Managing Director, D.E. Shaw and Co., L.P.
CEO and co-founder of BoostSuite
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Professor of Systems Biology, Columbia University
Cancer occurs when a group of cells in the body lose their ability to divide in an orderly fashion. Angiogenesis, or blood vessel growth, induced by a tumor allows it to continue growing. UCSD pathologist David Cheresh studies tumor angiogenesis and tumor cell invasion and metastasis. Scientists working in his lab have developed a number of inhibitors of tumor angiogenesis that are now being tested clinically in cancer patients. Two of these agents, Vitaxin and Celingitide, show promise for late stage cancer patients and appear safe with little or no side effects. Online information and registration is available here.